INmune Bio (NASDAQ:INMB) has received a $2.9M research grant from the National Institutes of Health (NIH), of which the company will receive $739k this year and $1.2M next year, with the balance to be received in 2022, to support a Phase 2 study of XPro1595 in patients with treatment resistant depression (TRD).
The trial will enroll patients with TRD that have biomarkers of inflammation and anhedonia (inability to feel pleasure). Neuroimaging biomarkers will be used to measure response to XPro1595.
The company will also host an accompanying Key Opinion Leader webinar at 1 p.m. ET on September 29 to provide additional information about the role of neuroinflammation in treatment-resistant depression.
XPro1595, the company’s lead drug, is an inhibitor of tumor necrosis factor (TNF) that is designed to neutralize soluble TNF (sTNF) without affecting trans-membrane TNF (tmTNF) or TNF receptors.
In July, the company announced that XPro1595 showed encouraging action in early-stage Alzheimer’s study.